Positive Results of Second Assessment of Sona’s GNR Technology from U.S. Nanotechnology Characterization Laboratory
Halifax, Nova Scotia — (Newsfile Corp. – April 17, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the second set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”). The assessment included analyses of two additional batches of Sona’s gold nanorods for consistency of physiochemical characterization and microbial contamination and endotoxin levels.
“Getting the approval of regulators to run clinical trials for targeted hyperthermia therapy (“THT”) will require a mountain of compelling data. These NCL assessments of the biocompatibility of our core, gold nanorod technology, coupled with the existing small animal study data for THT will provide us with a great base on which to build in the coming months.”, Sona’s CEO, David Regan, commented.
As with the NCL’s January assessment of three earlier batches of Sona’s gold nanorods, this new assessment did not detect any endotoxins or microbial contamination. The assessment also found “no significant differences between the two lots by DLS (dynamic light scattering) hydrodynamic size, zeta potential, or gold concentration”.
The NCL will continue to work with Sona to conduct further studies that may support any submission for the use of Sona’s gold nanorods in Sona’s THT to the US Food and Drug Administration (“FDA”), including a quantitation of the surfactant detected in the samples. The NCL was established by the National Cancer Institute (“NCI”) to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the FDA, and the National Institute of Standards and Technology (“NIST”).
